Day: February 23, 2021

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The Annual General Meeting of ALK-Abelló A/S will be held on Thursday 18 March 2021 at 4.00pm (CET) as a fully electronic Annual General Meeting. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.Shareholders who have registered their attendance can participate in the Annual General Meeting via VP’s VGM portal. The Annual General Meeting will also be webcast live at ALK’s website: https://ir.alk.net/agm.ALK-Abelló A/SFor further information please contact:Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525Media: Jeppe Ilkjær, mobile +45 3050 2014About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Ordinær generalforsamling i ALK-Abelló A/S afholdes torsdag den 18. marts 2021 kl. 16.00 som en fuldstændig elektronisk generalforsamling i henhold til vedhæftede indkaldelse med bestyrelsens fuldstændige forslag, som fremsættes på generalforsamlingen.Aktionærer, der har tilmeldt sig generalforsamlingen, vil kunne deltage via VP’s generalfor­samlingsportal. Generalforsamlingen kan desuden følges på ALK’s hjemmeside: https://ir.alk.net/da/agm.ALK-Abelló A/SFor yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Jeppe Ilkjær, mobil 3050 2014Om ALKALK er en global, specialiseret medicinalvirksomhed med fokus på allergi og allergisk astma. Virksomheden markedsfører allergi-immunterapi og andre produkter og serviceydelser til mennesker...

BOCA RATON, Fla, Feb. 23, 2021 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that the U.S. Patent and Trademark Office (USPTO) has granted the Company Patent No. 10,607,802 B2, titled “Three-Dimensional Beam Forming X-Ray Source.” This patent, which contains 31 separate claims, describes the method of beam splitting and sculpting found in the Sculptura™ System, the Company’s Anisotropic Radiation Therapy with Beam Sculpting™ capabilities and Robotic Respiratory Tracking for up to 17 different indications.“We are delighted that the USPTO has recognized our unique technology with the granting of this important patent, the first of its...

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three YearsLAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical stage development company focused on DNA based immunotherapy and next generation vaccines, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell $2 million of its unused New Jersey net operating losses (NOLs) for the tax years 2018 and 2019. The NOLs are typically sold at a small, single-digit discount to qualified companies with operations in New Jersey. As a result, the Company anticipates it will be able to transfer this credit and receive approximately $1.85 million of net cash proceeds. With this additional funding,...

— Former Deputy Regional Director to advance firm’s Diversity, Inclusion & Belonging mandate in new Executive role —TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) — Global design and technology firm, IBI Group (TSX:IBG), is pleased to announce the appointment of Audrey Jacob to Chief Operations Director. In this new Corporate Services role, Ms. Jacob joins the firm’s Executive team, and assumes responsibility for the Marketing & Communications and Human Resources functions globally, as well as the firm’s office leases across its 60+ global offices. She will also take a leadership role in advancing IBI Group’s mandate on Diversity, Inclusion & Belonging. Ms. Jacob previously held roles as Canada East Deputy Regional Director, and Toronto Office Lead, where she was responsible for the financial performance of the firm’s headquarters...

TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that the Uruguayan Ministry of Public Health, (Ministerio de Salúd Publica or “MSP”) has selected RAMM as a fulfilment and distribution partner for Uruguay’s COVID-19 vaccination program. Under the arrangement, RAMM will be responsible for the sterilization, packaging and distribution of syringes and other medical supplies for use in the country’s COVID-19 vaccination program. RAMM’s state-of-the-art GMP certified pharmaceutical facility was selected for the program upon satisfaction of the stringent requirements of the Ministry of Public Health.“We are pleased to play an integral role in Uruguay’s...

SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will participate at the following upcoming virtual investor conferences:Cowen 41st Annual Health Care ConferenceDate and Time: March 2, 2021 at 2:10 p.m. Eastern TimeSean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual breast cancer panel discussion.33rd Annual ROTH Growth ConferenceDate and Time: March 15, 2021 at 5:00 p.m. Eastern TimeSean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual women’s health panel discussion.About...

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences:Cowen 41st Annual Virtual Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET; andOppenheimer 31st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 9:20 a.m. ET.Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.About AgiosAgios is focused on discovering and developing novel investigational...